PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Regulation FD Disclosure
Item 7.01 Other Events.
presentations and participate in conferences with investors and
analysts in connection with the 29th>Annual ROTH
Conference in Dana Point, California. A copy of the Companys
presentation materials has been posted to the Companys website
and is attached hereto as Exhibit 99.1.
information, including the Exhibit, is furnished to Item 7.01 and
shall not be deemed to be filed for the purpose of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section. The information in
this Item 7.01 of this Current Report on Form 8-K will not be
deemed an admission as to the materiality of any information that
is required to be disclosed solely by Regulation FD.
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we can give no assurance that such expectations will
prove to be correct. Important factors that could impair the
Companys royalty assets or business are disclosed in the Risk
Factors contained in the Companys 2016 Annual Report on Form 10-K
filed with the Securities and Exchange Commission on March 1,
2017. All forward-looking statements are expressly qualified in
their entirety by such factors. We do not undertake any duty to
update any forward-looking statement except as required by law.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Presentation
|
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use. PDL BioPharma, Inc. (NASDAQ:PDLI) Recent Trading Information
PDL BioPharma, Inc. (NASDAQ:PDLI) closed its last trading session 00.00 at 2.15 with 1,419,409 shares trading hands.